Four-Times Daily ASA More Effective in Post-CABG Patients
(HealthDay News) — For patients undergoing coronary artery bypass graft (CABG) surgery, four-times daily acetyl-salicylic acid (ASA) seems more effective than once-daily 81mg or 325mg ASA, according to a study published online December 27 in the Journal of Thrombosis and Haemostasis.
Jeremy S. Paikin, MD, from McMaster University in Hamilton, Canada, and colleagues conducted a randomized study involving 100 patients undergoing CABG surgery to compare the effects of ASA 81mg once-daily, ASA 325mg once-daily, and ASA 81mg four-times daily. The authors compared the effect on serum thromboxane B2 (TXB2) suppression and arachidonate-induced platelet aggregation.
The researchers found that platelet counts decreased after surgery, reached a nadir on day two, then increased gradually. On the second or third postoperative day there was near complete suppression of TXB2; levels increased on subsequent days. Patients receiving ASA 81mg once-daily had the most marked increase, while the increase was less evident with four-times daily ASA 81mg. Median TXB2 levels were lower on postoperative day four with four-times daily ASA 81mg vs. once-daily ASA 81mg or 325mg. Suppression of platelet aggregation was more effective with ASA given four-times daily versus ASA 81mg or 325mg once-daily.
"Four-times daily ASA is more effective than ASA 81mg and 325mg once-daily at suppressing serum TXB2 formation and platelet aggregation immediately following CABG surgery," the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.